These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27997812)

  • 1. Why EMA should provide clearer guidance on the authorization of NBCDs in generic and hybrid applications.
    Garattini L; Padula A
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):243-245. PubMed ID: 27997812
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilars and safety issues.
    Dammacco F; Abbracchio MP; Gesualdo L; Goffredo F; Ronco C; Zanella A
    Leuk Lymphoma; 2009 Apr; 50(4):656-8. PubMed ID: 19373667
    [No Abstract]   [Full Text] [Related]  

  • 3. Biosimilars: considerations for an abbreviated pathway.
    Kozlowski S; Behrman R
    Leuk Lymphoma; 2009 Apr; 50(4):527-8. PubMed ID: 19373649
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.
    Palylyk-Colwell E; Jamali F; Dryden W; Friesen E; Koven S; Mohamed I; Osmond B; Alessi-Severini S; Sheldon L; Sheldon R; Tam Y; Tsuyuki R; Zhanel G
    J Pharm Pharm Sci; 1998; 1(1):2-7. PubMed ID: 10942966
    [No Abstract]   [Full Text] [Related]  

  • 5. Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation.
    Lunawat S; Bhat K
    Ther Innov Regul Sci; 2020 Sep; 54(5):991-1000. PubMed ID: 31960290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.
    Petrelli F; Caraffa A; Scuri S; Grappasonni I; Magrini E; Cocchini A
    Acta Biomed; 2019 May; 90(2):288-299. PubMed ID: 31125009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The similarity question for biologicals and non-biological complex drugs.
    Crommelin DJ; Shah VP; Klebovich I; McNeil SE; Weinstein V; Flühmann B; Mühlebach S; de Vlieger JS
    Eur J Pharm Sci; 2015 Aug; 76():10-7. PubMed ID: 25912826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A counterfeit drug treaty: great idea, wrong implementation.
    Bate R; Attaran A
    Lancet; 2010 Oct; 376(9751):1446-8. PubMed ID: 21036261
    [No Abstract]   [Full Text] [Related]  

  • 10. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations.
    Klein K; Stolk P; De Bruin ML; Leufkens HGM; Crommelin DJA; De Vlieger JSB
    Eur J Pharm Sci; 2019 May; 133():228-235. PubMed ID: 30953753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
    Walenga JM; Jackson CM; Kessler CM
    Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of generic ophthalmic drugs.
    Novack GD
    Ocul Surf; 2013 Jan; 11(1):54-6. PubMed ID: 23321360
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug Regulation and Pricing--Can Regulators Influence Affordability?
    Eichler HG; Hurts H; Broich K; Rasi G
    N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
    [No Abstract]   [Full Text] [Related]  

  • 14. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 15. When Is a Medicine Good Enough?: Science, Similarity, and the History of Generic Drugs.
    Greene JA
    Clin Pharmacol Ther; 2019 Feb; 105(2):290-291. PubMed ID: 30703267
    [No Abstract]   [Full Text] [Related]  

  • 16. The INN crowd.
    Nat Biotechnol; 2013 Dec; 31(12):1055. PubMed ID: 24316620
    [No Abstract]   [Full Text] [Related]  

  • 17. Nature Biotechnology responds.
    Nat Biotechnol; 2014 Feb; 32(2):132. PubMed ID: 24509756
    [No Abstract]   [Full Text] [Related]  

  • 18. Why are biosimilars much more complex than generics?
    Pagani E
    Einstein (Sao Paulo); 2019 Feb; 17(1):eED4836. PubMed ID: 30810585
    [No Abstract]   [Full Text] [Related]  

  • 19. [Generic prescription should be evaluated as new way of prescription in Denmark].
    Hellebek A; Søndergaaard J; Thirstrup S; Sales Y
    Ugeskr Laeger; 2012 Aug; 174(35):1974. PubMed ID: 22929572
    [No Abstract]   [Full Text] [Related]  

  • 20. Biosimilar peptides: need for pharmacovigilance.
    Joshi SR
    J Assoc Physicians India; 2011 Apr; 59 Suppl():44-7. PubMed ID: 21818998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.